



# MAGMA – A novel bioinformatics pipeline developed for integration of WGS in clinical care and tuberculosis control

T.H. Heupink<sup>1</sup>, L. Verboven<sup>1</sup>, A. Sharma<sup>2</sup>, V. Rennie<sup>1</sup>, R.M. Warren<sup>2</sup>, A. Van Rie<sup>1</sup>

## NGS for Tuberculosis Control

Could revolutionise TB control and improve patient outcomes

Determine drug resistance profile for individual patients

Monitor the emergence of drug resistance



Improve understanding of drug resistance mechanisms

Identify transmission events

## Challenges

- Clinical samples: complex bacterial communities and low *Mtb* burden
- Mtb* enrichment through subculturing is a slow process (6+ weeks)
- Limited infrastructure and human expertise in low-income countries
- Detection of mixed infection and heteroresistance

## Clinical *Mtb* Samples with High Contamination Loads



### UVP

Cannot analyse samples with contamination load >10%


### MTBSeq

Struggles to analyse samples with contamination load >60%

### MAGMA

Can call variants with high accuracy regardless of contamination load

## Samples with Low *Mtb* Burden



### UVP

Variable accuracy regardless of coverage

### MTBSeq

High accuracy at coverage >20x

### MAGMA

High accuracy at coverage <5x

## Heteroresistance | Mixed Infection

### Pipeline's ability to detect:

#### Minor Variants

X UVP

X MTBSeq

✓ MAGMA

#### Mixed Infection

X UVP

X MTBSeq

✓ MAGMA

Note: See Comparison with Deeplex (Poster P71)

## Conclusion

- All three pipelines perform similarly for standard analysis of WGS on high-quality *Mtb* DNA samples
- MAGMA outperforms other *Mtb*-specific pipelines in data with low coverage and high contamination
- MAGMA facilitates the 'real-time' WGS in routine care as it can analyse data from *Mtb* early primary liquid cultures
- Future prospects include development of user-friendly MAGMA platform, see oral presentation (OR10)